186 related articles for article (PubMed ID: 31745591)
1. Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interaction through in silico proteolysis and rational design.
Zou S; Liu J; Sun Z; Feng X; Wang Z; Jin Y; Yang Z
Cancer Chemother Pharmacol; 2020 Jan; 85(1):185-193. PubMed ID: 31745591
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
3. The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5.
Liu J; Feng X; Jin Y; Sun Z; Meng H; Zhang Z; Hu L; Yang Z
Oncotarget; 2017 Apr; 8(16):27189-27198. PubMed ID: 28423711
[TBL] [Abstract][Full Text] [Related]
4. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
5. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
Boohaker RJ; Sambandam V; Segura I; Miller J; Suto M; Xu B
Cancer Lett; 2018 Oct; 434():11-21. PubMed ID: 29920293
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
7. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.
Cheng B; Wang W; Niu X; Ren Y; Liu T; Cao H; Wang S; Tu Y; Chen J; Liu S; Yang X; Chen J
J Med Chem; 2020 Dec; 63(24):15946-15959. PubMed ID: 33264007
[TBL] [Abstract][Full Text] [Related]
9. A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity.
Tao H; Cheng L; Liu L; Wang H; Jiang Z; Qiang X; Xing L; Xu Y; Cai X; Yao J; Wang M; Qiu Z
Cancer Lett; 2020 Nov; 493():91-101. PubMed ID: 32805322
[TBL] [Abstract][Full Text] [Related]
10. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor.
Li Q; Quan L; Lyu J; He Z; Wang X; Meng J; Zhao Z; Zhu L; Liu X; Li H
Oncotarget; 2016 Oct; 7(40):64967-64976. PubMed ID: 27533458
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold.
Qin M; Cao Q; Wu X; Liu C; Zheng S; Xie H; Tian Y; Xie J; Zhao Y; Hou Y; Zhang X; Xu B; Zhang H; Wang X
Eur J Med Chem; 2020 Jan; 186():111856. PubMed ID: 31734021
[TBL] [Abstract][Full Text] [Related]
13. Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
Cai S; Chen Z; Wang Y; Wang M; Wu J; Tong Y; Chen L; Lu C; Yang H
Theranostics; 2021; 11(4):1970-1981. PubMed ID: 33408792
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy.
Liang Y; Luo H; Li X; Liu S; Habib A; Liu B; Huang J; Wang J; Yi H; Hu B; Zheng L; Xie J; Zhu N
Front Immunol; 2024; 15():1367040. PubMed ID: 38745661
[TBL] [Abstract][Full Text] [Related]
15. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
Tian H; Kang Y; Song X; Xu Y; Chen H; Gong X; Zhang W; Xu Y; Xia X; Gao X; Yao W
Cancer Lett; 2020 Apr; 476():170-182. PubMed ID: 32092355
[TBL] [Abstract][Full Text] [Related]
16. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
Gordon SR; Maute RL; Dulken BW; Hutter G; George BM; McCracken MN; Gupta R; Tsai JM; Sinha R; Corey D; Ring AM; Connolly AJ; Weissman IL
Nature; 2017 May; 545(7655):495-499. PubMed ID: 28514441
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Evaluation of
OuYang Y; Gao J; Zhao L; Lu J; Zhong H; Tang H; Jin S; Yue L; Li Y; Guo W; Xu Q; Lai Y
J Med Chem; 2021 Jun; 64(11):7646-7666. PubMed ID: 34037385
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
19. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
Li C; Zhang N; Zhou J; Ding C; Jin Y; Cui X; Pu K; Zhu Y
Cancer Immunol Res; 2018 Feb; 6(2):178-188. PubMed ID: 29217732
[TBL] [Abstract][Full Text] [Related]
20. The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
Schaer DA; Geeganage S; Amaladas N; Lu ZH; Rasmussen ER; Sonyi A; Chin D; Capen A; Li Y; Meyer CM; Jones BD; Huang X; Luo S; Carpenito C; Roth KD; Nikolayev A; Tan B; Brahmachary M; Chodavarapu K; Dorsey FC; Manro JR; Doman TN; Donoho GP; Surguladze D; Hall GE; Kalos M; Novosiadly RD
Clin Cancer Res; 2019 Dec; 25(23):7175-7188. PubMed ID: 31409612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
